Introduction {#S0001}
============

Bronchoscopic lung volume reduction (BLVR) is a valuable treatment option for patients with severe COPD and emphysema, aimed at reducing hyperinflation of the lung.[@CIT0001] BLVR using endobronchial valves (EBV) and lung volume reduction coils (LVRC) have been studied most extensively and demonstrated to be effective, with an acceptable safety profile.[@CIT0002]

Dedicated patient selection for BLVR is essential in achieving clinically meaningful results after treatment. For example, for the EBV treatment, the absence of interlobar collateral ventilation is necessary to achieve successful outcomes and for the LVRC treatment superior outcomes are observed in patients with very severe static hyperinflation and absence of significant airway disease.[@CIT0003]--[@CIT0007]

Several questions on patient selection for BLVR remain unanswered. For example, it is unknown what proportion of patients referred for BLVR is potentially eligible for any form of BLVR treatment and to our knowledge, this group of patients has not been well characterized in the literature. Furthermore, the development of new insights in BLVR treatment during this period led to changes in the inclusion and exclusion criteria for these treatments which potentially could influence the proportion of selected patients.

Therefore, we aimed to investigate 1) which proportion of patients that were referred to our hospital were actually selected for BLVR treatment; 2) the differences in characteristics and survival between patients that were and were not selected for BLVR; 3) to what extent applying updated criteria for eligibility would have affected the selection rate.

Patients and Methods {#S0002}
====================

Study Design and Patient Population {#S0002-S2001}
-----------------------------------

We performed a retrospective analysis of the first 1500 patients who were consecutively referred to assess eligibility for BLVR treatment between March 2007 and October 2014, from 62 different hospitals in the Netherlands to our hospital. Given the retrospective and anonymous nature of the analyses, this research did not fall within the scope of the WMO (Dutch Medical Research with Human Subjects Law) and therefore review by a medical ethical committee was not required.

Evaluation of Eligibility {#S0002-S2002}
-------------------------

Patient selection for BLVR in our hospital starts with the referral of a patient by their pulmonary physician. Referring physicians are requested to include recent lung function results (spirometry and body plethysmography), chest computed tomography (HRCT) scan, and a complete medical history in their referrals. During a multidisciplinary team meeting, a first selection is made. Potential BLVR candidates are invited to our hospital for a consultation with an interventional pulmonologist.

Treatment {#S0002-S2003}
---------

Patients that were eligible for BLVR treatment were included in clinical trials investigating EBV,[@CIT0003],[@CIT0008]--[@CIT0011] LVRC,[@CIT0012]--[@CIT0015] polymeric lung volume reduction,[@CIT0016] pneumostoma[@CIT0017]--[@CIT0019] and airway bypass stents[@CIT0020] or in our regular EBV treatment program (BREATH-NL: NCT02815683).

Outcomes {#S0002-S2004}
--------

The primary outcome of this study was the selection rate for BLVR treatment. Secondary outcomes were derived from the referral documentation and included demographics, lung function (spirometry and body plethysmography), smoking status, oxygen therapy use and maintenance anticoagulant use. Furthermore, the medical history of all patients was screened for a selection of comorbidities. All available CT scans were visually reviewed and assessed by JBAW for the presence of specific characteristics, these assessments were supervised by DJS.

The degree of emphysema destruction was scored on a 0 to 4 qualitative Likert scale with higher scores indicating more emphysematous destruction ([Figure 1](#F0001){ref-type="fig"}).[@CIT0021],[@CIT0022] In case of ineligibility for BLVR, we reported the reasons why patients were found not to be eligible for treatment. The survival status of the referred patients was verified with the Dutch government (Personal Records Database) on June 16, 2019.Figure 1Qualitative scale of emphysematous destruction, scored on a 0 to 4 scale with higher scores indicating more emphysematous destruction.

Theoretical Model {#S0002-S2005}
-----------------

We applied some of the most recent inclusion and exclusion criteria for EBV and LVRC, according to the guidelines,[@CIT0001] on our cohort to assess the proportion of patients eligible for these treatments and whether this proportion was different from the proportion of patients actually selected for these treatments. The criteria applied for EBV treatment included forced expiratory volume in 1 s (FEV~1~) between 20% and 50% of predicted, residual volume (RV) ≥175% of predicted, RV/total lung capacity (TLC) ratio of ≥0.58, visually intact major fissure (left or right) and emphysema destruction ≥2 on destruction scale ([Figure 1](#F0001){ref-type="fig"}).

The criteria applied for LVRC included FEV~1~ between 20% and 50% of predicted, RV ≥200% of predicted, RV/TLC ratio of ≥0.58 and emphysema destruction ≥2 on the destruction scale ([Figure 1](#F0001){ref-type="fig"}).

Statistical Analysis {#S0002-S2006}
--------------------

Differences in patient characteristics between the group that was selected for treatment and the group that was not were analyzed using an independent-samples *T*-test in case of normal distribution of data and a Mann--Whitney-*U* test in case of non-normal distribution. A Chi-squared test was used in the case of categorical data. Due to the explorative nature of the CT data, only demographic data are presented and no statistical analysis was performed. Survival time was defined as the time after the date of discussion in the multidisciplinary team meeting until the date of verification with the Dutch government. Survival was analyzed using the Kaplan--Meier method. Comparison in survival between the groups selected or not selected for treatment was performed using the Mantel--Cox log-rank test and comparison in survival between EBV and LVRC treatment was performed using Breslow's test. All statistical analyses were performed using SPSS version 23 (IBM, New York, NY, USA). P-values \<0.05 were considered statistically significant.

Results {#S0003}
=======

In total, 1500 patients (50% female) were included in our analysis, with a mean age of 62 years and FEV~1~ of 33±14% of predicted (additional patient characteristics are shown in [Table 1](#T0001){ref-type="table"}). From this group, 651 patients (43%) were invited for a consultation in our hospital. Of the total referred population 282 (19%) patients were selected for a clinical trial or regular treatment program and therefore a total of 1218 (81%) patients were considered not eligible for BLVR (see [Figure 2](#F0002){ref-type="fig"} for patient flowchart).Table 1Patient CharacteristicsAll ReferralsSelected for TreatmentNot Selected for TreatmentP valueNumber of patients15002821218Age (years)62±959±863±9P\<0.001Female750 (50%)179 (63%)571 (47%)P\<0.001BMI (kg/m^2^)24±524±424±5P=0.02Pack-years (years)38±1836±1638±18P=0.18FEV~1~ (L)0.9±0.50.8±0.31.0±0.5P\<0.001FEV~1 ~predicted (%)33±1428±834±15P\<0.001FVC (L)2.8±1.02.6±0.92.8±1.0P=0.01FVC predicted (%)79±2177±1979±22P=0.08RV (L)4.8±1.34.9±1.14.7±1.3P=0.03RV predicted (%)219±56237±46215±58P\<0.001TLC (L)7.8±1.67.8±1.57.8±1.6P=0.77TLC predicted (%)130±18135±15129±19P\<0.001Current smoker123 (8%)10 (4%)113 (9%)P\<0.01Ex-smoker1051(70%)263 (94%)788 (65%)P\<0.001Never smoker16 (1%)2 (1%)14 (1%)P=0.52Unknown302 (20%)6 (2%)296 (24%)P\<0.001Oxygen therapy418 (28%)80 (28%)338 (28%)P=0.84Maintenance anticoagulant use280 (19%)44 (16%)236 (19%)P=0.14Participation in previous pulmonary rehabilitation or weekly physiotherapy684 (46%)174 (62%)510 (42%)P\<0.001Weekly physiotherapy567 (38%168 (60%)399 (33%)P\<0.001[^1] Figure 2Study flowchart.**Abbreviation:** PLVR, polymeric lung volume reduction.

Out of the group of 282 patients that were selected for a bronchoscopic treatment, 175 patients (62%) were selected for EBV, 93 patients (33%) for LVRC, 3 patients (0.2%) for airway bypass stents, 9 patients (3%) for polymeric lung volume reduction and 2 patients (0.1%) for a pneumostoma.

Patients selected for BLVR were significantly younger (59 versus 63 years), had a lower FEV~1~ (28% versus 34% of predicted) and a higher RV (237% versus 215% of predicted) compared to the group of patients not selected for BLVR (all P\<0.001).

The most frequently encountered reasons for ineligibility for BLVR treatment were: absence of a suitable target lobe for treatment (18%), unsuitable disease phenotype for treatment (chronic bronchitis, frequent exacerbations, asthma) (18%) and insufficient hyperinflation of the lungs (16%). See [Table 2](#T0002){ref-type="table"} for the complete list of contra-indications.Table 2Contraindications in Patients Not Selected for BLVRContraindicationPrevalenceNumber of patients1218Number of contraindicationsMean ± standard deviation1.3±0.9Median (range)1 (0--5)Absence of suitable target lobe for treatment221 (18%)Unsuitable disease phenotype (chronic bronchitis, frequent exacerbations, asthma)219 (18%)Insufficient hyperinflation of the lungs197 (16%)Presence of comorbidity162 (13%)Homogeneous distribution of emphysema125 (10%)Incomplete interlobar fissures109 (9%)Patient renounced treatment95 (8%)Pulmonary function testing outcomes not meeting minimum hyperinflation and/or airway obstruction requirements95 (8%)No trial available at moment of evaluation94 (8%)Low degree of emphysema destruction83 (7%)Did not stop smoking for \>6 months79 (7%)Did not yet participate in pulmonary rehabilitation73 (6%)Maintenance anticoagulant use54 (5%)Too high degree of emphysema destruction53 (4%)Presence of bullae47 (4%)Paraseptal emphysema phenotype47 (4%)High level of exercise capacity43 (4%)Suspicious nodules in the lung that require follow-up38 (3%)Too poor condition for treatment35 (3%)Prior thoracic surgery31 (3%)Body mass index too high or too low26 (2%)Pulmonary Hypertension22 (2%)Alpha-1 antitrypsin deficiency15 (1%)Lung transplanted before BLVR treatment3 (0.2%)[^2]

The CT scans of 1211 patients (81%) could be assessed, for 289 patients assessment was not possible because of scan unavailability or insufficient image quality for assessment. The proportion of patients with a homogeneous and heterogeneous distribution of emphysema was similar (52% versus 48%). Upper lobe predominant emphysema was observed more often than lower lobe predominant emphysema (71% versus 29%). The left major fissure was found to be visually intact in 44% of patients, the right major in 25% of patients and the right minor fissure in 12% of patients (see [Table 3](#T0003){ref-type="table"}).Table 3CT CharacteristicsAll ReferralsSelected for TreatmentNot Selected for TreatmentNumber of patients15002821218Scans available1211274937Mild centrilobular\
Severe centrilobular\
Panlobular\
Paraseptal\
No emphysema428 (35%)\
440 (36%)\
189 (16%)\
146 (12%)\
8 (0.7%)80 (29%)\
113 (41%)\
66 (24%)\
15 (6%)\
0 (0%)348 (37%)\
327 (35%)\
123 (13%)\
131 (14%)\
8 (1%)Distribution homogeneous/heterogeneous (%)48/5231/6953/47Upper/Lower lobes predominant (%)71/2964/3675/25Destruction LUL 1/2/3/4 (%)40/38/19/235/46/19/142/35/19/3Destruction LLL 1/2/3/4 (%)55/31/11/152/33/13/256/31/10/1Destruction RUL 1/2/3/4 (%)37/35/24/333/39/26/238/34/23/3Destruction RLL 1/2/3/4 (%)56/32/10/153/32/13/256/31/9/1Left major fissure (intact/\>90%intact/\<90%intact/unknown (%)44/26/29/258/20/22/040/28/31/2Right major fissure (intact/\>90% intact/\<90% intact/unknown (%)25/32/41/136/31/33/022/33/44/2Right minor fissure (intact/\>90% intact/\<90% intact/unknown (%)12/14/72/312/18/70/011/13/72/3Bronchopathy666 (55%)140 (51%)526 (56%)Mild bronchiectasis\
Severe bronchiectasis151 (13%)\
20 (2%)30 (11%)\
1 (0.4%)121 (13%)\
19 (2%)Giant bullae195 (16%)21 (8%)174 (19%)Nodules requiring follow up89 (7%)27 (10%)62 (7%)Fibrosis23 (2%)2 (0.7%)21 (2%)Pleural pathology13 (1%)2 (0.7%)11 (1%)Suspect for pulmonary hypertension148 (12%)25 (9%)123 (13%)[^3]

[Table 4](#T0004){ref-type="table"} displays the reported comorbidities. Patients referred for BLVR had an average of 1.4 comorbidities and the most frequently encountered comorbidities were hypertension (22%), confirmed or suspected asthma (18%) and coronary artery disease (10%). Patients selected for BLVR had significantly less comorbidities compared to the group of patients not selected for BLVR (1.1 versus 1.4, P\<0.01).Table 4Comorbidities Reported in the Referral DocumentationComorbidityAll ReferralsSelected for TreatmentNot Selected for TreatmentNumber of patients15002821218Number of comorbidities\*mean±standard deviation1.4±1.41.1±1.21.4±1.5median (range)1 (0--11)1 (0--6)1 (0--11)Hypertension323 (22%)72 (26%)251 (21%)Confirmed or suspected asthma270 (18%)58 (21%)212 (17%)Coronary artery disease153 (10%)16 (6%)137 (11%)Dyslipidemia117 (8%)20 (7%)97 (8%)Diabetes112 (8%)15 (5%)97 (8%)Osteoporosis105 (7%)19 (7%)86 (7%)Obesity (BMI\>30)105 (7%)12 (4%)93 (8%)Atrial fibrillation84 (6%)4 (1%)80 (7%)Myocardial infarction82 (6%)6 (2%)76 (6%)Cerebrovascular incident76 (5%)12 (4%)64 (5%)Alpha-1 antitrypsin deficiency70 (5%)16 (6%)54 (4%)Peripheral artery disease59 (4%)6 (2%)53 (4%)Heart failure54 (4%)5 (2%)49 (4%)Depression54 (4%)11 (4%)43 (4%)Pulmonary embolus48 (3%)10 (4%)38 (3%)Pulmonary hypertension46 (3%)1 (0.4%)45 (4%)Gastro-oesophageal reflux disease43 (3%)7 (3%)36 (3%)Degenerative joint disease38 (3%)4 (1%)34 (3%)Anxiety35 (2%)7 (3%)28 (2%)Obstructive sleep apnea syndrome33 (2%)5 (2%)28 (2%)Gastric ulcer24 (2%)2 (1%)22 (2%)Pulmonary malignancy21 (1%)2 (1%)19 (2%)Anemia20 (1%)0 (0%)20 (2%)Chronic kidney disease15 (1%)0 (0%)15 (1%)Pulmonary fibrosis10 (0.7%)0 (0%)10 (0.8%)Liver cirrhosis2 (0.1%)1 (0.4%)1 (0.1%)[^4]

The survival status of 1272 patients (85%) could be verified. The overall median survival was 2316 days (95% CI: 2146--2485 days). The median follow-up was 2351 days (95% CI: 2451--2514 days). Patients that were referred to our hospital but were not invited for consultation had a median survival of 1808 days (95% CI: 1622--1994) and patients who were invited for consultation but who were not selected for treatment had a median survival of 2524 days (95% CI: 2234--2814). Patients that were selected for BLVR lived significantly longer than the group of patients that was not selected for BLVR (median 3060 versus 2079 days, P\<0.001), see [Figure 3](#F0003){ref-type="fig"}. No significant survival difference was observed between patients who were selected for EBV treatment and those who were selected for LVRC (P=0.45).Figure 3Kaplan-Meier plots of survival. (**A**) Survival of the patients that were selected for treatment and the patients that were not selected for treatment. (**B**) Survival of the patients that were selected for EBV, selected for LVRC, invited to our hospital for consultation but not selected for BLVR, not selected for BLVR and not invited to our hospital for consultation.**Abbreviations:** EBV, endobronchial valve treatment; LVRC, lung volume reduction coil treatment; BLVR, bronchoscopic lung volume reduction; MDT, multidisciplinary team meeting.

Theoretical Model {#S0003-S2001}
-----------------

When applying some of the currently established inclusion and exclusion criteria for endobronchial valve treatment and lung volume reduction treatment, we identified 283 patients eligible for EBV treatment (19%) while 175 patients (12%) were actually selected for EBV in this cohort and 144 patients (10%) would currently be eligible for LVRC while 93 patients (6%) were actually selected for LVRC ([Figure 4](#F0004){ref-type="fig"}).Figure 4Eligibility for EBV and LVRC after application of current inclusion and exclusion criteria. (**A**) Eligible patients for EBV treatment. (**B**) Eligible patients for LVRC treatment.**Abbreviations:** N, number of patients; FEV~1~, forced expiratory volume in 1 s; RV, residual volume; TLC, total lung capacity; EBV, endobronchial valve treatment; LUL, left upper lobe; RUL, right upper lobe; LLL, left lower lobe; RLL, right lower lobe; LVRC, lung volume reduction coil treatment.

Discussion {#S0004}
==========

Only one out of five patients who were referred for BLVR treatment to our hospital were selected for BLVR treatment. Ineligibility for BLVR treatment was most often caused by the absence of a suitable target lobe for treatment, an unsuitable disease phenotype for treatment and insufficient lung hyperinflation. Overall survival in the group of patients referred for BLVR was poor with a median survival of approximately 6 years.

To our knowledge, this is the largest study investigating patients referred for BLVR eligibility assessment. In a recent study by Polke et al, who studied patients that were referred to a BLVR expert center in Heidelberg (Germany), a higher proportion of patients were found to be eligible for BLVR treatment, possibly caused by a more strict preselection of patients for referral.[@CIT0023] The same study also found the absence of a suitable target lobe to be the most frequent contra-indication for BLVR, which is in line with the results of our study.[@CIT0023]

Only a small proportion of the already preselected group of patients that were considered to be eligible for BLVR by the referring physician is selected for BLVR treatment. This highlights both the need for improved referral strategies on the one hand and the important need for additional therapeutic options for patients with severe COPD on the other hand. Alternative interventions for BLVR include lung volume reduction surgery or lung transplantation; however, both treatments suffer from huge limitations related to the invasiveness of the procedure, scarce availability and strict selection procedures. Patients with a severe chronic bronchitis phenotype of COPD are a common example of an unsuitable disease phenotype for BLVR. Both endobronchial treatment with liquid nitrogen cryospray and targeted lung denervation are currently under development for this phenotype. Liquid nitrogen cryospray is a treatment aimed at inducing an airway tissue healing effect by destroying the hyperplastic goblet cells and excess submucous glands.[@CIT0024] Target lung denervation is a treatment designed to decrease airway resistance and mucus hyper section, by inhibiting parasympathetic pulmonary nerves, using radiofrequency ablation therapy.[@CIT0025]

New insights into BLVR treatment caused inclusion and exclusion criteria for these treatments to change over time, which might have affected the proportion of patients considered eligible for BVLR. For example, a previous contra-indication for EBV trials included the presence of alpha-1 antitrypsin deficiency, but these patients are now considered eligible for treatment.[@CIT0003],[@CIT0026] When we applied the most recent inclusion and exclusion criteria on our cohort, we observed a discrepancy between the number of patients that were eligible for treatment and those who were actually selected for treatment. This could be the result of the fact that not all treatments were available at all times during the time frame of this study, the clinical trial context with strict in and exclusion criteria or because we applied only a selection of the most stringent criteria in our model.

A significant survival benefit was observed for the group of patients that was selected for BLVR treatment, when compared to the group that was not selected for treatment. This survival benefit was already observed in several previous studies which demonstrated that when successful lobar atelectasis is achieved after EBV treatment, patients have a substantial, persisting survival benefit.[@CIT0027]--[@CIT0029] Structural survival data for the LVRC treatment are not yet available. We acknowledge that the survival benefit observed in the group of patients that were selected for treatment might have not only been due to a direct result of the actual intervention but also caused by the exclusion of patients that were too frail, due to any cause, for treatment. On the other hand, both the degree of hyperinflation and airway obstruction were higher in the group selected for treatment, suggesting the selection of patients with severe disease for treatment. In addition, given that most treatments in this cohort took place in the early phase of the development of these treatments, the current data might actually underestimate the survival benefit of these treatments.

Patients selected for BLVR had significantly less comorbidities than patients who were not selected for BLVR. On average, the referred patients had more than one comorbidity. However, this was still lower than in a study by Putcha et al, possibly caused by the underreporting of comorbidities by the referring physicians in our cohort or because of the fact that the referring physicians already referred a preselected population due to study selection criteria on comorbidity.[@CIT0030],[@CIT0031]

We assessed the CT characteristics of the referred patients and found the left major fissure to be most often intact on the CT scans of the referred patients, followed by the right major fissure and the right minor fissure. The proportion of visually intact fissures was in line with previously published data on this topic, and also in agreement with the latest clinical trials investigating EBV and intrabronchial valves, in which the left upper and left lower lobe were selected for treatment in more than 75% of cases.[@CIT0011],[@CIT0032],[@CIT0033]

This study has several limitations: first of all, our population is representative of the group of patients referred to a BLVR center but not of the total population of patients with severe emphysema, and can therefore not serve to accurately assess the proportion of eligible patients for BLVR in the total population of patients with emphysema. Second, inherent to the retrospective nature of this study, we had to rely on the quality of the referral documentation from other hospitals. Incomplete or incorrect referral documentation might have especially affected the data presented on comorbidity, which was based on the medical history included in the referral documentation, probably leading to an underestimation of comorbidity.[@CIT0031] Third, the CT scans were of very different quality and settings, because referral material was used, making a preferred quantitative assessment not possible.[@CIT0034] These scans were assessed by one reviewer only (JBAW), under supervision of one of the authors (DJS), a task that in an ideal setting would have been performed by a panel of reviewers. Fourth, since these were the first 1500 BLVR referrals sent to our hospital, most patients were treated in a clinical trial context, which probably led to a more strict selection compared to treatment outside the clinical trial context, underestimating the number of patients eligible for BLVR treatment. Fifth, it would have been of additional value to include a survival prediction index like BODE, but we did not have the necessary data available to perform this.[@CIT0035]

A strength of our study is the large number of patients that were included in this retrospective study. Another strength of our study is the fact that we were able to verify the survival status of our patients with the Dutch government, which increased the reliability of our survival data.

Future research might include the development of a model that is able to predict the à priori chances of BLVR eligibility. Such a model could assist both physicians and patients in deciding whether referral to a BLVR center is indicated. Indeed, the right patient should be referred for the right treatment, to improve efficiency and avoid the burden for the patient. Future research is needed to identify the size of the potential pool of patients eligible for BLVR treatment as a previous study by Pietzsch et al suggested that BLVR currently is only used in a small proportion of patients with severe emphysema.[@CIT0036]

In conclusion, we found that only a small proportion of patients that are referred for BLVR treatment is eligible for a BLVR treatment, indicating a need for the development of new therapies for this group of patients and better referral tools. Furthermore, our data suggest that selection for BLVR is associated with a significant survival benefit.
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BLVR, bronchoscopic lung volume reduction; COPD, chronic obstructive pulmonary disease; CT, computed tomography; EBV, endobronchial valves; FEV~1~, forced expiratory volume in 1 s; LVRC, lung volume reduction coil; RV, residual volume; TLC, total lung capacity.
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[^1]: **Notes:** Data are presented as the number of patients (%), mean ± standard deviation or percentage of the predicted value ± standard deviation. Differences in patient characteristics between the selected and not selected group for treatment were analyzed using a 2-samples *T*-test or Chi-square test.

    **Abbreviations:** BMI, body mass index; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; RV, residual volume; TLC, total lung capacity.

[^2]: **Notes:** Data are presented as number of contraindications (percentage of patients with contraindication), mean ± standard deviation, median (range).

    **Abbreviation:** BLVR, bronchoscopic lung volume reduction.

[^3]: **Notes:** Data is presented as number of patients (percentage of patients) or as percentage of cases. Destruction score based on a 1 to 4 Likert scale, with higher scores indicating more severe emphysematous destruction.

    **Abbreviations:** CT, computed tomography; LUL, left upper lobe; LLL, left lower lobe; RUL, right upper lobe; RLL, right lower lobe.

[^4]: **Notes:** Data are presented as the number of patients (percentage of patients), mean ± standard deviation or median (range). Differences in the number of comorbidities were assessed using Mann--Whitney *U*-test. \*P\<0.01.

    **Abbreviation:** BMI, body mass index.
